CD80 (B7.1) and CD86 (B7.2) induce EBV-transformed B cell apoptosis through the Fas/FasL pathway

International Journal of Oncology

Volumn 43, Issue 5, 2013, Pages 1531-1540

  Park, Ga Bin ^a   Kim, Yeong Seok ^a   Lee, Hyun Kyung ^b   Cho, Dae Ho ^c   Kim, Daejin ^a   Hur, Dae Young ^a  

^a Inje University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Sookmyung Women's University   (South Korea)

Author keywords

Apoptosis; B cells; CD80; CD86; Epstein Barr virus

Indexed keywords

ACETYLCYSTEINE; APOPTOSIS INDUCING FACTOR; B7 ANTIGEN; CASPASE; CD86 ANTIGEN; CYTOCHROME C; FAS LIGAND; N BENZYLOXYCARBONYL VAL ALA ASP FLUOROMETHYLKETONE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL DISRUPTION; CELL STIMULATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS INFECTION; HUMAN; HUMAN CELL; MITOCHONDRION; MOLECULE; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; UPREGULATION; VIRUS CELL TRANSFORMATION;

ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, CD95; B-LYMPHOCYTES; CELL TRANSFORMATION, VIRAL; CELLS, CULTURED; EPSTEIN-BARR VIRUS INFECTIONS; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; HUMANS; SIGNAL TRANSDUCTION;

EID: 84885048327     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2091     Document Type: Article

References (40)

1. Epstein MA, Barr YM and Achong BG: Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 15: 702-703, 1964.
2. Caldwell RG, Wilson JB, Anderson SJ and Longnecker R: Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9: 405-411, 1998.
3. Henderson S, Huen D, Rowe M, Dawson C, Johnson G and Rickinson A: Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci USA 90: 8479-8483, 1993.
4. Rathmell JC, Townsend SE, Xu JC, Flavell RA and Goodnow CC: Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 87: 319-329, 1996.
5. Rathmell JC, Cooke MP, Ho WY, Grein J, Townsend SE, Davis mM and Goodnow CC: CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells. Nature 376: 181-184, 1995
6. Lagresle C, Mondière P, Bella C, Krammer PH and Defrance T: Concurrent engagement of CD40 and the antigen receptor protects naive and memory human B cells from APO-1/Fas-mediated apoptosis. J Exp Med 183: 1377-1388, 1996.
7. Jacobson BA, Panka DJ, Nguyen KA, Erikson J, Abbas AK and Marshak-Rothstein A: Anatomy of autoantibody production: dominant localization of antibody-producing cells to T cell zones in Fas-deficient mice. Immunity 3: 509-519, 1995.
8. Arcipowski KM, Stunz LL, Graham JP, Kraus ZJ, Vanden Bush TJ and Bishop GA: Molecular mechanisms of TNFR-associated factor 6 (TRAF6) utilization by the oncogenic viral mimic of CD40, latent membrane protein 1 (LMP1). J Biol Chem 286: 9948-9955, 2011.
9. Arcipowski KM and Bishop GA: Roles of the kinase TAK1 in TRAF6-dependent signaling by CD40 and its oncogenic viral mimic, LMP1. PLoS One 7: e42478, 2012.
10. Graham JP, Arcipowski KM and Bishop GA: Differential B lymphocyte regulation by CD40 and its viral mimic, latent membrane protein Immunol Rev 237: 226-248, 2010.
11. Mongini PK, Tolani S, Fattah RJ and Inman JK: Antigen receptor triggered upregulation of CD86 and CD80 in human B cells: augmenting role of the CD21/CD19 co-stimulatory complex and IL-4. Cell Immunol 216: 50-64, 2002.
12. Evans DE, Munks MW, Purkerson JM and Parker DC: Resting B lymphocytes as APC for naive T lymphocytes: dependence on CD40 ligand/CD40. J Immunol 164: 688-697, 2000.
13. Clatza A, Bonifaz LC, Vignali DA and Moreno J: CD40-induced aggregation of MHC class II and CD80 on the cell surface leads to an early enhancement in antigen presentation. J Immunol 171: 6478-6487, 2003.
14. Bluestone JA: New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2: 555-559, 1995.
15. Jirapongsananuruk O, Hofer MF, Trumble AE, Norris DA and Leung DY: Enhanced expression of B7.2 (CD86) in patients with atopic dermatitis: a potential role in the modulation of IgE synthesis. J Immunol 160: 4622-4627, 1998.
16. Lenschow DJ, Walunas TL and Bluestone JA: CD28/B7 system of T cell costimulation. Annu Rev Immunol 14: 233-258, 1996.
17. Rathmell JC, Fournier S, Weintraub BC, Allison JP and Goodnow CC: Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4(+) T cells. J Exp Med 17: 651-659, 1998.
18. Ikemizu S, Gilbert RJ, Fennelly JA, Collins AV, Harlos K, Jones EY, Stuart DI and Davis SJ: Structure and dimerization of a soluble form of B7-1. Immunity 12: 51-60, 2000.
19. Bajorath J, Peach RJ and Linsley PS: Immunoglobulin fold characteristics of B7-1 (CD80) and B7-2 (CD86). Protein Sci 3: 2148-2150, 1994.
20. Heath AW, Chang R, Harada N, Argumedo LS, Gordon J, Hannum C, Campell D, Shanafelt AB, Clark EA, Torres R and Howard M: Antibodies to murine CD40 stimulate normal B lymphocytes but inhibit proliferation of B lymphoma cells. Cell Immunol 152: 468-480, 1993.
21. Borriello F, Sethna MP, Boyd SD, Schweitzer AN, Tivol EA, Jacoby D, Strom TB, Simpson EM, Freeman GJ and Sharpe AH: B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity 6: 303-331, 1997.
22. Suvas S, Singh V, Sahdev S, Vohra H and Agrewala JN: Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 277: 7766-7775, 2002.
23. Kim YS, Park GB, Lee HK, Song H, Choi IH, Lee WJ and Hur DY: Cross-linking of B7-H1 on EBV-transformed B cells induces apoptosis through reactive oxygen species production, JNK signaling activation, and fasL expression. J Immunol 181: 6158-6169, 2008.
24. Song H, Park G, Kim YS, Hur I, Kim H, Ryu JW, Lee HK, Cho DH, Choi IH, Lee WJ and Hur DY: B7-H4 reverse signaling induces the apoptosis of EBV-transformed B cells through Fas ligand up-regulation. Cancer Lett 266: 227-237, 2008.
25. Park GB, Song H, Kim YS, Sung M, Ryu JW, Lee HK, Cho DH, Kim D, Lee WJ and Hur DY: Cell cycle arrest induced by engagement of B7-H4 on Epstein-Barr virus-positive B-cell lymphoma cell lines. Immunology 128: 360-368, 2009.
26. Andreyev AY, Kushnareva YE and Starkov AA: Mitochondrial metabolism of reactive oxygen species. Biochemistry 70: 200-214, 2005.
27. Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G and Vandenabeele P: Toxic proteins released from mitochondria in cell death. Oncogene 23: 2861-2874, 2004.
28. Cregan SP, Dawson VL and Slack RS: Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 23: 2785-2796, 2004.
29. Bornkamm GW and Hammerschmidt W: Molecular virology of Epstein-Barr virus. Phil Trans R Soc Lond B Biol Sci 356: 437-459, 2001.
30. Kempkes B, Spitkovsky D, Jansen-Durr P, Ellwart GW, Kremmer E, Delecluse HJ, Rottenberger C, Bornkamm GW and Hammerschmidt W: B cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J 14: 88-96, 1995.
31. Yamada S, Shinozaki K and Agematsu K: Involvement of CD27/CD70 interactions in antigen-specific cytotoxic T-lymphocyte (CTL) activity by perforin-mediated cytotoxicity. Clin Exp Immunol 130: 424-430, 2002.
32. Gordon J, Millsum MJ, Guy GR and Ledbetter JA: Resting B lymphocytes can be triggered directly through the CDw40 (Bp50) antigen. A comparison with IL-4-mediated signaling. J Immunol 140: 1425-1430, 1988.
33. Goldstein MD and Watts TH: Identification of distinct domains in CD40 involved in B7-1 induction or growth inhibition. J Immunol 157: 2837-2843, 1996.
34. Nakajima A, Kodama T, Morimoto S, Azuma M, Takeda K, Oshima H, Yoshino S, Yagita H and Okumura K: Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. J Immunol 161: 1901-1907, 1998.
35. Bergamo A, Bataille R and Pellat-Deceunynck C: CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2. Br J Haematol 97: 652-655, 1997.
36. Snow AL, Chen LJ, Nepomuceno RR, Krams SM, Esquivel CO and Martinez OM: Resistance to Fas-mediated apoptosis in EBV-infected B cell lymphomas is due to defects in the proximal Fas signaling pathway. J Immunol 167: 5404-5411, 2001.
37. Tepper CG and Seldin MF: Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. Blood 94: 1727-1737, 1999.
38. Le Clorennec C, Youlyouz-Marfak I, Adriaenssens E, Coll J, Bornkamm GW and Feuillard J: EBV latency III immortalization program sensitizes B cells to induction of CD95-mediated apoptosis via LMP1: role of NF-kappaB, STAT1, and p53. Blood 107: 2070-2078, 2006.
39. Durandy A, Le Deist F, Emile JF, Debatin K and Fischer A: Sensitivity of Epstein-Barr virus-induced B cell tumor to apoptosis mediated by anti- CD95/Apo-1/fas antibody. Eur J Immunol 27: 538-543, 1997.
40. Li-Weber M and Krammer PH: Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system. Semin Immunol 15: 145-157, 2003.